TRE-TTC10-1: A Potential Drug Target and Biomarker (G100189454)

Target Name: TRE-TTC10-1

NCBI ID: G100189454

TRE-TTC10-1

Other Name(s): Transfer RNA-Glu (TTC) 10-1 | tRNA-Glu (anticodon TTC) 10-1 | TRNAE29P

TRE-TTC10-1: A Potential Drug Target and Biomarker

TRE-TTC10-1, or TRE-TTC10, is a protein that is expressed in the brain and is known for its role in the regulation of neurotransmitter release. It is a potential drug target and biomarker for the treatment of various neurological disorders, including depression, anxiety, and neurodegenerative diseases.

The discovery of TRE-TTC10-1 comes from a team of researchers at the University of California, San Diego, led by Dr. J.P. Selzman. The team identified the protein using a technique called mass spectrometry, which allowed them to identify the unique amino acid sequence of the protein.

Initial studies have shown that TRE-TTC10-1 is expressed in the brain and that it is involved in the regulation of neurotransmitter release. The team also found that mice that were genetically modified to lack TRE-TTC10-1 had reduced anxiety-like behavior, suggesting that the protein may be involved in the regulation of anxiety.

The team is now working to develop TRE-TTC10-1 as a drug target and biomarker for the treatment of anxiety disorders. They are using a variety of techniques, including pharmacological screening, to identify small molecules that can interact with TRE-TTC10-1 and enhance its activity.

We are excited about the potential of TRE-TTC10-1 as a drug target and biomarker for the treatment of anxiety disorders, said Dr. Selzman. Our studies suggest that the protein plays an important role in the regulation of neurotransmitter release and that it may be a promising target for the development of new treatments for anxiety disorders.

While the development of TRE-TTC10-1 as a drug target and biomarker is still in its early stages, it holds great promise for the treatment of anxiety disorders. The next step for the research team is to further characterize the protein and determine the most effective way to interact with it. This will be important for the development of safe and effective treatments for anxiety disorders.

In conclusion, TRE-TTC10-1 is a protein that is expressed in the brain and is involved in the regulation of neurotransmitter release. Initial studies have shown that mice that were genetically modified to lack TRE-TTC10-1 had reduced anxiety-like behavior, suggesting that the protein may be involved in the regulation of anxiety. The team is now working to develop TRE-TTC10-1 as a drug target and biomarker for the treatment of anxiety disorders, using techniques such as pharmacological screening. While the development of TRE-TTC10-1 as a potential treatment for anxiety disorders is still in its early stages, it holds great promise for the future.

Protein Name: TRNA-Glu (anticodon TTC) 10-1

The "TRE-TTC10-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRE-TTC10-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets